

# **A Population-Based Cross-Sectional Investigation of COVID-19 Hospitalizations and Mortality Among Autistic People**

Dewy Nijhof<sup>\*1</sup>, Filip Sosenko<sup>\*1</sup>, Daniel Mackay<sup>1</sup>, Michael Fleming<sup>1</sup>, Bhautesh D Jani<sup>1</sup>, Jill Pell<sup>1</sup>, Chris Hatton<sup>2</sup>, Deborah Cairns<sup>1</sup>, Angela Henderson<sup>1</sup>, Laura Ward<sup>1</sup>, Ewelina Rydzewska<sup>3</sup>, Maria Gardani<sup>3</sup>, Elliot Millington<sup>1</sup>, Craig Melville<sup>1</sup>, on behalf of the CVD-COVID-UK/COVID-IMPACT Consortium

<sup>\*</sup>Joint first author

<sup>1</sup>University of Glasgow, School of Mental Health and Wellbeing

<sup>2</sup>Manchester Metropolitan University, Faculty of Health and Education

<sup>3</sup>University of Edinburgh, School of Health in Social Science

Corresponding author: Dewy Nijhof, [dewy.nijhof@glasgow.ac.uk](mailto:dewy.nijhof@glasgow.ac.uk)

## Abstract

**Background:** Current evidence suggests the possibility that autistic people may be at more risk of COVID-19 infection, hospitalisation, and mortality than the general population. Previous studies, however, are either limited in scale or do not investigate potential risk factors. Whilst many risk factors have been speculated to be responsible for severe COVID-19, this research has focused on general population samples. **Methods:** Using data-linkage and a whole-country population, this study modelled associations between autism and COVID-19 hospitalisation and mortality risk in adults, investigating a multitude of clinical and demographic risk factors. **Results:** Autistic adults had higher rates of hospitalisation, Standardised Incident Ratio 1.6 in 2020 and 1.3 in 2021, and mortality, Standardised Mortality Ratio 1.52 in 2020 and 1.34 in 2021, due to COVID-19 than the general population. In both populations, age, complex multimorbidity and vaccination status were the most significant predictors of COVID-19 hospitalisation and mortality. Effects of psychotropic medication varied by class. **Conclusions:** Although similar factors exhibited a positive association with heightened risk of severe COVID-19 in both the autistic and general populations, with comparable effect sizes, mortality rates were elevated among the autistic population as compared to the general population. Specifically, the presence of complex multimorbidity and classification of prescribed medications may emerge as particularly significant predictors of severe COVID-19 among individuals within the autistic population due to higher prevalence of complex multimorbidity in the autistic population and variability in the association between medication classes and severe COVID-19 between both populations, though further research is needed.

**Keywords** Autism Spectrum Disorder, ASD, COVID-19, Morbidity, Hospitalisation, Mortality, Population study

## Introduction

In the UK, the earliest COVID-19 cases were identified in late January 2020 and a pandemic was officially declared in March 2020 (1). Increasing evidence suggests increased risk of susceptibility and severe disease progression of COVID-19 for certain conditions (2,3). For example, conditions such as diabetes and obesity were deemed risk factors (2). Subgroups within the population have been shown to be disproportionately at risk of COVID-19 but the full extent of these risk factors is unclear (4). Most research has focused on ethnic subpopulations or high-risk patient groups, but little is known about the risks of COVID-19 for autistic people<sup>1</sup>.

Autism Spectrum Disorder (ASD) is defined as a neurodevelopmental disorder. Its main characteristics are differences in social communication and interaction and repetitive and restrictive behaviours, including differences in sensory preferences (5). Whilst several genetical and immunological characteristics of autism have been hypothesised to affect COVID-19 infection, severity, and mortality risk (6–8), few studies have focused on differences in the clinical profiles of autistic people and the general population. Both physical and mental health conditions, such as obesity (2,3), gastrointestinal symptoms (3) and mental health conditions (9,10) have been associated with increased COVID-19 infection, disease severity and mortality in the general population. Several of these conditions often co-occur alongside autism (11,12). Specifically, psychotic disorders and mood disorders are more commonly experienced by autistic people (12) and have been linked with increased risk of COVID-19 mortality in the general population (9). It is further argued by some that sensory difficulties experienced by autistic people can hinder their ability to adhere to COVID-19 measures, such as wearing personal protective equipment (PPE) or strict hygiene rules, thereby increasing the potential for exposure to sources of infection (13,14). Similarly, differences in communication and social isolation can impact the ability to understand and follow COVID-19 related advice and affect help-seeking behaviours and patient-clinician communication in relation to health (13,14).

Furthermore, long-term conditions and multimorbidity prevalence is often accompanied by polypharmacy, the use of multiple medicines, which has been shown to contribute to increased COVID-19 morbidity in the general population (15,16) but has not been investigated in autistic populations. Yet, polypharmacy and more particularly prescription of antipsychotics are prevalent both amongst autistic children (17) and autistic adults (18,19). Commonly prescribed medications, including antipsychotics, antidepressants, and anticholinergic medication, are known to have the

---

<sup>1</sup> Throughout this paper we use identity-first language or neutral terms ('autistic people' or 'people on the autism spectrum') rather than person-first language as a result of the article by Kenny et al. (53) highlighting the preference for identity-first language by the majority of autistic people and their families.

potential to increase the risk of pneumonia through immunosuppressive and other protective mechanisms (20). Moreover, antipsychotics have been shown to exert anti-inflammatory effects and disrupt immune responses (21), which may contribute even further to adverse COVID-19 outcomes. Indeed, several studies (22,23) and a meta-analysis (9) found increased risk of COVID-19 mortality associated with exposure to antipsychotics in the general population. Furthermore, recent research has raised the issue of potential adverse outcomes due to drug-drug interactions of prescribed medications and COVID-19 pharmacotherapies (24,25).

Few studies have investigated the association between autism and COVID-19 and results are inconsistent. One study investigating 36 autistic children in a residential facility did not find higher prevalence nor severity of COVID-19 in autistic young adults, though it should be mentioned that study controls (n=35) were of older age than the autistic group (6). Further, this study did not differentiate between young adults with autism only and young adults with co-occurring autism and intellectual disabilities (ID). Previous research suggests that people with ID are at higher risk of severe COVID-19 (27,28) and thus results may be confounded. Moreover, facilities in which individuals live in close proximity have been found to increase infection rates (29), confounding results even further. A meta-analysis found increased risk of COVID-19 mortality in autistic people only in unadjusted estimates and no evidence of increased intensive care admissions, but did not separate autism from ID or other developmental disorders (9). In contrast, a population-based study found that autistic males over 16 years had higher COVID-19 hospitalisation rates after stratifying for age, gender and morbidities that have been shown to increase COVID-19 infection rates compared to the general population (30).

As such, there is conflicting evidence regarding the risk of COVID-19 infection and outcome severity amongst autistic people. To the best of our knowledge, no studies have investigated whether this risk extends to COVID-19 mortality. Moreover, whilst previous studies speculated on the underlying causes of increased risk, none have systematically studied clinical risk factors for COVID-19 in the autistic population. Using a country-wide sample, the current study aimed to investigate whether there are differences in COVID-19 hospitalisation and mortality rates between autistic people and the general population. Furthermore, this study aimed to explore the association between demographic and clinical risk factors and severe COVID-19 in the autistic population.

## Methods

### *Study Design*

This was a cross-sectional study using a whole-country population. Data was subdivided into two time periods: (1) including the month in which the first lockdown started in the UK, 1 March 2020, to 31 December 2020; (2) 1 January 2021 to 31 December 2021. This division was made due to the vaccination programme not coming into full effect until 2021. While the first vaccination was received on 8 December 2020, due to vaccination priorities and logistics it is reasonable to assume that the majority of the study population had not received a COVID-19 vaccination in 2020. However, by the end of 2021, a greater proportion of the population had likely been afforded the opportunity to receive at least one COVID-19 vaccination. Consequently, COVID-19 rates in 2021 may vary significantly from those in 2020.

### *Data sources and definitions*

This study was conducted on behalf of the CVD-COVID-UK/COVID-IMPACT Consortium (31) (coordinated by the BHF Data Science Centre). The following datasets were used: GPES Data for Pandemic Planning and Research (GDPPR), Hospital Episode Statistics (HES), COVID-19 Second Generation Surveillance System (SGSS), Vaccination Events (VE), Civil Registry Deaths from the ONS (ONS-D), NHS BSA Dispensed Medicine (NHS BSA). The GDPPR, HES, SGSS, VE and NHS BSA datasets are updated through the National Health Service (NHS) and processed by NHS England, after which the data is available for secondary uses, such as research. The ONS dataset is updated through the Office for National Statistics (ONS). Approvals were obtained from the research consortium and from the University of Glasgow Ethics Committee.

Long-term conditions (LTCs) were identified using a list of 35 common conditions in the general UK population (32) using phenotypes sourced from the Cambridge Multimorbidity Score, using the GDPPR and HES datasets (33). This list includes conditions that have previously been identified as risk factors for COVID-19 infection and severity, for example obesity, diabetes, and hypertension (2). The list includes both physical and mental conditions but excludes autism. Complex multimorbidity was defined by the presence of at least three of those 35 LTCs of which at least one was physical (34). Polypharmacy was defined as the concurrent use of five prescription medications or more (35). Polypharmacy, use of antipsychotics, antidepressants, anticonvulsants, and psychotropic medication were identified using British National Formulary (BNF) codes. Prescribing data was examined if it fell within the following parameters: dispensed within 15 days before the date of testing positive for COVID-19 (cut-off date) and within 240 days before this cut-off date (35).

In the context of this study, severe COVID-19 included those who had a positive COVID-19 laboratory test and were hospitalised for COVID-19 or died from COVID-19 within 28 days from the test or died without a positive test, but COVID-19 is listed as a cause of death on their death certificate (any diagnostic position).

## **Population**

The study covered the whole adult (i.e., over 18 years old) population of England who were alive on 1 January 2020 and had at least one primary care record (for the purpose of establishing their autism status). Autistic individuals were identified using SNOMED CT diagnosis codes in the primary care dataset (GDPPR). Some evidence suggests that people with ID have a larger risk of severe COVID-19 (27,28). Further, research suggests that there may be complex interactions at play in relation to mortality and causes of mortality when it comes to comorbid autism-ID (36). As such, this study opted to investigate severe COVID-19 in autism only. Participants who had diagnoses for both autism and ID were included in the comparison group to control for potential confounding (having ID is a major risk factor for COVID-19 hospitalisation or death (27). Although there is a possibility that this may marginally reduce any differences found between autistic people and the comparison group, we maintain the stance that as a result of this decision, any inferences drawn from this study will be more generalisable to autistic people without intellectual disabilities -which remains the main focus of the study.

The whole population consisted of 180,860 (of which 28.5% female) autistic people and 48,383,120 (of which 50.4% female) people in the comparison group, hereafter referred to as general population. Age distribution in the two populations differed significantly, with a median age of 47 [interquartile range (IQR) 30] years in the general population and 26 [IQR 12] in the autistic population (t-test,  $p$ -value <0.001). This corresponds to known low levels of identification or recording of autism in primary care records for people aged over 30 years old (37) as well as diagnostic advances and autism awareness over the years (38). Demographic and health characteristics of the study participants are shown in *Table 1*. Characteristics for the 35 long-term conditions for both the whole population and analysis sample- (i.e., those infected with and hospitalised for COVID-19) can be found in the *Appendix*.

## **[TABLE 1]**

From this whole population, participants were included in the analysis if they met at least one of two criteria: (1) they had a registered positive COVID-19 laboratory test (identified through GDPPR) or (2) COVID-19 was listed as a cause of death (either primary or other contributing causes using ICD-10 code U07.1 or U07.2) on their death certificate. In the case of multiple positive tests, the first instance was

used. Information about LTCs, vaccination status, and prescribed medications were extracted using the time of positive test result.

### **Data Analysis**

Data was analysed within NHS England's Secure Data Environment service for England, made available via the British Heart Foundation Data Science Centre's CVD-COVID-UK/COVID-IMPACT Consortium (31), using a combination of Python (v3.7), SQL, and R (v4.03) scripts. The analysis was performed according to a pre-specified analysis plan published on GitHub (39), along with the phenotyping and analysis code.

Demographic (age, sex, ethnicity, Index of Multiple Deprivation (IMD)) and health characteristics (LTCs, complex multimorbidity, vaccination status, prescribed medications) were explored and compared using means, standard deviations, and t-tests for continuous data and frequency, percentages, and  $\chi^2$ -tests for categorical data. Standardised Incident Ratios (SIRs) and Standardised Mortality Ratios (SMRs) were calculated for 2020 and 2021 separately. SIRs were also calculated for hospitalisation (while positive for COVID-19) and severe COVID-19 (hospitalisation or death due to COVID-19). A binary logistic regression model was used to model prediction of severe COVID-19 infection using demographic and health factors as predictors. Note that modelling of antipsychotic, antidepressant, and anticonvulsant medication did not control for diagnosis of related mental health conditions due to the possibility of prescription of these medications for unrelated issues. There is evidence to suggest that overprescription, particularly of psychotropic medications, is a significant issue in relation to autistic adults (37,40) with and without psychiatric conditions (41). Further, though research on these medication classes in autistic people is scarce, limited evidence suggests variable effects regarding efficacy and tolerance of psychotropic medication in autistic people (41).

Further hierarchical logistic modelling was used to assess the contribution of each predictor category. Blinder-Oaxaca decomposition analysis was applied to decompose the mean difference in the risk of severe COVID-19 between the two population groups for each of the predictor categories used in the regression modelling (42).

Logistic regression was chosen as the main modelling technique rather than survival analysis due to its allowance for a larger number of records to be included. (Individuals who had a PCR test already in hospital, and those who died without a PCR test, cannot be included in survival analysis). Still, survival analysis in the form of a Cox proportional hazards model was conducted as a sensitivity test of the logistic modelling.

## Results

### *Demographics*

A total of 32,375 autistic people and 8,425,470 general population individuals were hospitalised with a positive COVID-19 test. Table 1 shows the demographic and health characteristics of autistic people and the general population used in the analysis (i.e., tested positive for COVID-19). Due to the younger age structure in the autistic population, both unadjusted and age-adjusted values are shown. The autistic group had a significantly different population structure, demonstrated by a lower percentage of females, higher chance of living in a deprived area (evidenced by lower mean IMD decile) and a higher percentage of white ethnicity. Autistic adults were equally likely as the general population to be vaccinated for COVID-19. Polypharmacy was more prevalent in the autistic population, with the mean numbers of prescription medications being 5.1 (SD 6.0) compared to 2.9 (SD 4.5) for the general population. Similarly, use of psychotropic, antipsychotic, antidepressant and anticonvulsant medications, was higher within the autistic population.

Autistic adults were also more likely to experience complex multimorbidity. From the list of 35 most common conditions in the UK, only three were not significantly higher for autistic adults (bronchiectasis, chronic kidney disease, and multiple sclerosis; see Appendix for full list). A few conditions stood out due to particularly higher prevalence in the autistic population: stroke/transient ischaemic attack, schizophrenia/bipolar disorder, psychoactive substance misuse, Parkinson's disease, diabetes, depression, dementia, asthma, anxiety/other neurotic disorders, and anorexia/bulimia.

### *Incidence, mortality and survival analysis*

Table 2 shows the SIRs for autistic adults who were hospitalised due to COVID-19 or who classify as having severe COVID-19 (i.e., taking together COVID-19 hospitalisations and COVID-19 deaths). The ratios show a higher incidence of both hospitalisation and severe COVID-19 for autistic adults in comparison to the general population, although a decline over time is visible from 2020 to 2021.

[TABLE 2]

Table 3 shows the Age Standardised Mortality Rate (ASMR) and Standardised Mortality Rates (SMR). ASMR takes the European Standard Population 2013 as reference and SMR takes the general population from the study sample as reference. Whilst ASMRs were higher for both groups within the study sample, the autistic population had particularly high mortality rates compared to the European Standard Population. Within the study sample, mortality rates for autistic adults were similarly increased compared to the general population. Similar to incidence rates, a decline from 2020 to 2021 is visible.

[TABLE 3]

*Modelling of risk factors*

Logistic regression modelling has been employed to investigate risk factors. The final model included two versions sharing core predictor variables and differed only in the aspect of medications. Model A focused on polypharmacy while model B focused on psychotropic medication.

Table 4 shows the results from the logistic regression models A and B. For both the autistic and general population, several factors were positively associated with increased risk of severe COVID-19 with similar effect sizes: age, ethnicity, complex multimorbidity (count of long-term conditions), polypharmacy (count of prescription medication), and antipsychotic prescription. Interestingly, the effect of complex multimorbidity varies by the extent of polypharmacy and vice versa. The effect of either risk factor is stronger when the score for the other is low. Again, effect sizes were similar between the two groups.

[TABLE 4]

Anticonvulsant prescription was significantly but weakly positively associated with increased risk for the general population only. Whereas Asian/Asian British ethnicity was the only ethnicity at risk for the autistic population, Black/Black British ethnicity was most at risk for the general population followed by Other, Asian/Asian British and Mixed ethnicity. Additionally, the effects of ethnicity and antipsychotic prescription on severe COVID-19 risk were more profound for the general population. Effects of long-term condition count were more pronounced for the autistic population. Contrastingly, female sex, Pfizer and Moderna vaccination, and antidepressant prescription were associated with decreased risk of severe COVID-19 for both the autistic and general population. Number of COVID-19 vaccination doses and AstraZeneca vaccination were significantly associated with decreased risk for the general population only. Antidepressant prescription effects were more pronounced for the autistic population. Table 5 shows the results from the survival analysis showing similar trends in associations, thus supporting findings from the logistic regression models.

[TABLE 5]

Hierarchical logistic modelling (Table 6) indicated that age, vaccination status and LTC count were the most important predictors for modelling severe COVID-19 infection in both autistic adults and the general population.

[TABLE 6]

Figure 1 visualises results from the Blinder-Oaxaca Decomposition analysis to decompose the mean difference in risk of severe COVID-19 between the autistic and general population groups into two components: the endowment effect, showing how much of the mean difference between the autistic and general population group is due to different distributions of the variable, and the coefficient effect, showing how much of the mean difference between the two groups is due to different influences of the same variable. As Figure 1 shows, the difference in non-age-adjusted probability of severe COVID-19 (0.066 in the general population, 0.033 in the autism group) can largely be attributed to the younger age profile of adults with autism.

[FIGURE 1]

## Discussion

This study aimed to explore COVID-19 in autism by investigating hospitalisation and mortality rates and exploring the association between demographic and clinical risk factors and their contributions to severe COVID-19 in autistic people. Previous studies investigating COVID-19 in autistic people produced conflicting results. Similar to a previous population-based study [34], our findings provide further evidence for the increased risk of hospitalisation (SIR 2020: 1.6, SIR 2021: 1.3) and mortality (SMR 2020: 1.52, SMR 2021: 1.34) of autistic adults due to COVID-19.

Exploration of demographic and clinical factors through regression modelling showed similar risk factors for the autistic and general population, with a few exceptions. Whereas all minority ethnicities were predictive of severe COVID-19 for the general population, only Asian/Asian British ethnicity was a significant predictor for the autistic population. This may be due to the different distribution of ethnicity between the two groups, with non-white ethnicities being less prevalent in the autistic population affecting sample size for those ethnicities (see Table 1). Similarly, female sex had a more protective effect for the general population than for the autistic population which may be explained due to the male bias in autism prevalence (43).

Number of COVID-19 vaccination doses only differed when not age-adjusted, however, the brands of vaccination had differing effects in the two populations. For both the general and autistic population, most people had received either Pfizer or AstraZeneca. Modelling of the predictors showed that while Pfizer was a significantly protective factor for severe COVID-19 for both populations, AstraZeneca was only significantly protective for the general population. Moderna was received the least by both populations and was found to be the most protective factor out of all predictors. There was no difference in the total number of vaccination doses received by either population.

The number of long-term conditions was the most important predictor of severe COVID-19 for the autistic population but not for the general population. Though the current study did not investigate individual associations between the long-term health conditions and COVID-19 hospitalisation and mortality, it is possible that this finding is due to the different clinical profile of the autistic population. Complex multimorbidity in general but particularly mental health conditions such as depression, dementia, anxiety and schizophrenia were more prevalent in the autistic study population. Previous research identified associations between increased risk of COVID-19 mortality and psychotic disorders, mood disorders and substance use disorders (9,10). The finding that the number of long-term conditions emerged as a significant predictor of severe COVID-19 in the autistic population, but not in the general population, underscores the intricate nature of multimorbidity in this group. However, this paper did not delve into the individual associations between long-term health conditions and COVID-19 outcomes. It is plausible that medication regimen, coupled with the presence of multimorbidity, may potentially lead to complex interactions that influence COVID-19 outcomes. Therefore, future research endeavours should aim to untangle the effects of medication regimen and the composition of multimorbidity in the autistic population on COVID-19 outcomes, warranting a separate and focused investigation.

Further, survival modelling showed that similarity in the number of prescriptions and the number of long-term conditions decreased the risk of severe COVID-19. In other words, low values of one variable paired with high values of the other were associated with higher risk of severe COVID-19. This may suggest that well-treated conditions and appropriate use of prescription medications may be a protective factor for severe COVID-19. Although this was found for both the autistic and general population, there is evidence to suggest that the health needs of autistic people are sometimes overlooked (44,45) or exacerbated by barriers in accessing medical care (46). Furthermore, despite similar effect sizes in the two populations, mortality rates were higher for the autistic population. Our findings highlight the importance and potentially far-reaching impact of addressing health inequalities experienced by autistic people.

Whilst polypharmacy was not included amongst the most important predictors in the hierarchical model for either the autistic or general population, further exploration suggests that this might be due to different effects of the medication class as we found, for both the autistic and general population, antipsychotic medication to be predictive of severe COVID-19 whereas antidepressant medication was protective. Furthermore, antipsychotic prescription was more predictive of severe COVID-19 in the general population whereas antidepressant prescription was more protective for the autistic population. Potentially, this could be due to differences in how these prescriptions are targeted in the two populations. For example, these medication classes are prescribed to autistic people on a more

widespread basis with antipsychotics being prescribed in absence of comorbid psychiatric conditions (41) The finding of protective effects of antidepressant prescription corresponds to prior research suggesting lower infection rates and decreased COVID-19 severity in patients using antidepressants in the general population (47,48). Whilst there are contradictory findings, pooled effects seem to indicate a protective effect of antidepressants against severe COVID-19 (47).

Due to abovementioned targeting of prescription medications in the autistic population and potential of prescription medications to be used for a multitude of conditions, our study did not match prescribed medications to existing conditions as this would not be an accurate representation of the use of medications in the autistic population. As such, we are unable to ascertain whether there is a potentially mediating effect between medication and condition on severe COVID-19. For example, several studies provide evidence that psychiatric conditions such as schizophrenia, depression and anxiety have higher COVID-19 mortality rates (9,10). Results from the hierarchical modelling suggest that the long-term condition is indeed a more significant risk factor than polypharmacy. However, the classes of medication explored in this study can be prescribed for a multitude of conditions and, thus, were not linked to specific long-term conditions. In addition, there are concerns that there may be adverse reactions of prescription medication and COVID-19 treatments (20). Due to the unavailability of COVID-19 treatment data, this study was unable to ascertain whether prescription medication was taken during the hospital stay and whether there could be potential reactions with COVID-19 treatments provided. Additionally, exploring the effects of differing combinations of prescription medication(s) and long-term conditions was beyond the scope of the current study. However, our results suggest that this may be a viable target for future research.

## **Strengths and limitations**

This study has several strengths. The study makes use of a whole-country population of autistic individuals and the general population. This large sample size ensures a representative sample, thereby reducing sampling bias. The combination of the large sample size and the use of validated datasets further strengthens the validity and robustness of the results. Moreover, inclusion criteria for autism are based on clinical diagnoses, using both older and newer diagnosis codes relevant to autism. This allows us to better capture people on the spectrum and, thus, better represent the autistic population in England.

A limitation is that, in earlier stages of the pandemic, community incidence of COVID-19 is likely underreported as testing was not yet standard practice and availability of tests was limited. However, it is likely that testing rates do not differ between people with and without autism. Similarly, case

fatality rates may be inflated due to lack of testing in these earlier stages. Additionally, whilst the dataset makes use of a whole-country population dataset, it should be noted that the final merged dataset contained a larger number of records than the recorded population size of England. This may be due to duplication of records, incorrect matching of NHS and death records, or people not registered as living in the UK receiving NHS treatment. However, effects on results reported in this study are likely to be minimal due to its use of rates and ratios, though caution should be exercised when interpreting absolute values.

Due to the use of autism identification through SNOMED CT diagnosis codes through primary care data, it is possible that the autistic study population does not fully capture the autistic population in England. Previous studies have indeed identified gaps in identification of autistic people over 30 years old within primary care (37). Moreover, it is possible that some autistic individuals are not registered with primary care and thus were not identified in this dataset.

## Conclusion

To conclude, our results show that autistic adults are at higher risk of hospitalisation or death due to COVID-19 as compared to the general population. Whilst demographic and clinical risk factors are similar for the autistic and general population, our results suggest that complex multimorbidity and prescription medication class may be of particular importance for the autistic population and should be further researched.

## Declarations

### Ethics approval and consent to participate

The North-East – Newcastle and North Tyneside 2 research ethics committee provided ethical approval for the CVD-COVID-UK/COVID-IMPACT research programme (REC No 20/NE/0161) to access, within secure trusted research environments, unconsented, whole-population, de-identified data from electronic health records collected as part of patients' routine healthcare. The need for informed consent was waived by the North-East – Newcastle and North Tyneside 2 research ethics committee. All methods were carried out in accordance with relevant guidelines and regulations.

### Availability of data and materials

The data used in this study are available in NHS England's Secure Data Environment (SDE) service for England, but as restrictions apply they are not publicly available (49).

The CVD-COVID-UK/COVID-IMPACT programme led by the BHF Data Science Centre (50) received approval to access data in NHS England's SDE service for England from the Independent Group

Advising on the Release of Data (IGARD) (51) via an application made in the Data Access Request Service (DARS) Online system (ref. DARS-NIC-381078-Y9C5K) (52).

The CVD-COVID-UK/COVID-IMPACT Approvals & Oversight Board (31) subsequently granted approval to this project to access the data within NHS England's SDE service for England. The de-identified data used in this study were made available to accredited researchers only. Those wishing to gain access to the data should contact [bhfdsc@hdruk.ac.uk](mailto:bhfdsc@hdruk.ac.uk) in the first instance.

### **Competing interests**

The authors declare that they have no competing interests.

### **Funding**

The British Heart Foundation Data Science Centre (grant No SP/19/3/34678, awarded to Health Data Research (HDR) UK) funded co-development (with NHS England) of the Secure Data Environment service for England, provision of linked datasets, data access, user software licences, computational usage, and data management and wrangling support, with additional contributions from the HDR UK Data and Connectivity component of the UK Government Chief Scientific Adviser's National Core Studies programme to coordinate national COVID-19 priority research. Consortium partner organisations funded the time of contributing data analysts, biostatisticians, epidemiologists, and clinicians.

The associated costs of accessing data in NHS England's Secure Data Environment service for England, for analysts working on this study, were funded by the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics, which is funded by UK Research and Innovation (grant ref: MC\_PC\_20058).

The Baily Thomas Charitable Fund funded staff (FS) time on this project.

### **Acknowledgements**

This work was carried out with the support of the BHF Data Science Centre led by HDR UK (BHF Grant no. SP/19/3/34678). This study makes use of de-identified data held in NHS England's Secure Data Environment service for England and made available via the BHF Data Science Centre's CVD-COVID-UK/COVID-IMPACT consortium. This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make health relevant data available for research.

The authors would like to thank The Baily Thomas Charitable Fund for funding staff costs on this study.

## Data Availability Statement

For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

## References

1. GOV.UK. 2 Years of COVID-19 on GOV.UK - Government Digital Service [Internet]. [cited 2023 Sep 7]. Available from: <https://gds.blog.gov.uk/2022/07/25/2-years-of-covid-19-on-gov-uk/>
2. Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). *Diabetes Metab Res Rev* [Internet]. 2021 Feb 1 [cited 2023 Jul 16];37(2):e3377. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/dmrr.3377>
3. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. *J Med Virol* [Internet]. 2021 Mar 1 [cited 2023 Jul 16];93(3):1449–58. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26424>
4. Constantino JN, Sahin M, Piven J, Rodgers R, Tschida J. The Impact of COVID-19 on Individuals with Intellectual and Developmental Disabilities: Clinical and Scientific Priorities. *Am J Psychiatry* [Internet]. 2020 Nov 1 [cited 2023 Jul 16];177(11):1091–3. Available from: <https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.20060780>
5. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. 5th ed. Arlington: American Psychiatric Publishing; 2013.
6. Lima ME de S, Barros LCM, Aragão GF. Could autism spectrum disorders be a risk factor for COVID-19? *Med Hypotheses*. 2020 Nov 1;144:109899.
7. Croonenberghs J, Bosmans E, Deboutte D, Kenis G, Maes M. Activation of the Inflammatory Response System in Autism. *Neuropsychobiology* [Internet]. 2002 Jan 1 [cited 2023 Jul 17];45(1):1–6. Available from: <https://dx.doi.org/10.1159/000048665>
8. Brondino N, Bertoglio F, Forneris F, Faravelli S, Borghesi A, Damiani S, et al. A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects. *Brain Sci* 2021, Vol 11, Page 860 [Internet]. 2021 Jun 28 [cited 2023 Jul 17];11(7):860. Available from: <https://www.mdpi.com/2076-3425/11/7/860/htm>
9. Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, et al. Mental Disorders and Risk of Covid-19 Related Mortality, Hospitalization and Intensive Care Unit Admission: A Systematic Review and Meta-Analysis. *SSRN Electron J*. 2021 May 15;
10. Toubasi AA, AbuAnzeh RB, Tawileh HBA, Aldebei RH, Alryalat SAS. A meta-analysis: The mortality and severity of COVID-19 among patients with mental disorders. *Psychiatry Res* [Internet]. 2021 May 1 [cited 2023 Jul 18];299:113856. Available from: [/pmc/articles/PMC7927594/](https://pmc/articles/PMC7927594/)
11. Rydzewska E, Dunn K, Cooper SA. Umbrella systematic review of systematic reviews and meta-analyses on comorbid physical conditions in people with autism spectrum disorder. *Br J Psychiatry* [Internet]. 2021 Jan 1 [cited 2023 Jul 17];218(1):10–9. Available from: <https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/umbrella-systematic-review-of-systematic-reviews-and-metaanalyses-on-comorbid-physical-conditions-in-people-with-autism-spectrum->

485 disorder/EC3473487B4B26DA18E1BFB634BB2390

486 12. Hossain MM, Khan N, Sultana A, Ma P, McKyer ELJ, Ahmed HU, et al. Prevalence of comorbid  
487 psychiatric disorders among people with autism spectrum disorder: An umbrella review of  
488 systematic reviews and meta-analyses. Vol. 287, Psychiatry Research. 2020.

489 13. Eshraghi AA, Li C, Alessandri M, Messinger DS, Eshraghi RS, Mittal R, et al. COVID-19:  
490 overcoming the challenges faced by individuals with autism and their families. The Lancet  
491 Psychiatry [Internet]. 2020 Jun 1 [cited 2023 Jul 17];7(6):481–3. Available from:  
492 <http://www.thelancet.com/article/S2215036620301978/fulltext>

493 14. Mutluer T, Doenyas C, Aslan Genc H. Behavioral Implications of the Covid-19 Process for  
494 Autism Spectrum Disorder, and Individuals' Comprehension of and Reactions to the Pandemic  
495 Conditions. Front Psychiatry. 2020 Nov 16;11:561882.

496 15. Iaccarino G, Grassi G, Borghi C, Ferri C, Salvetti M, Volpe Massimo M. Age and Multimorbidity  
497 Predict Death Among COVID-19 Patients. Hypertension [Internet]. 2020 Aug 1 [cited 2023 Jul  
498 17];76(2). Available from:  
499 <https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.120.15324>

500 16. McKeigue PM, Kennedy S, Weir A, Bishop J, McGurnaghan SJ, McAllister D, et al. Relation of  
501 severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT  
502 case-control study. BMC Med [Internet]. 2021 Dec 1 [cited 2023 Jul 17];19(1):1–11. Available  
503 from: <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-021-01907-8>

504 17. Spencer D, Marshall J, Post B, Kulakodlu M, Newschaffer C, Dennen T, et al. Psychotropic  
505 Medication Use and Polypharmacy in Children With Autism Spectrum Disorders. Pediatrics  
506 [Internet]. 2013 Nov 1 [cited 2023 Jul 17];132(5):833–40. Available from:  
507 </pediatrics/article/132/5/833/31738/Psychotropic-Medication-Use-and-Polypharmacy-in>

508 18. Lake JK, Balogh R, Lunsy Y. Polypharmacy profiles and predictors among adults with autism  
509 spectrum disorders. Res Autism Spectr Disord. 2012 Jul 1;6(3):1142–9.

510 19. Vohra R, Madhavan S, Sambamoorthi U, StPeter C, Poe S, Dwibedi N, et al. Prescription Drug  
511 Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-  
512 Sectional Analysis. Drugs - Real World Outcomes [Internet]. 2016 Dec 1 [cited 2023 Jul  
513 17];3(4):409–25. Available from: [https://link.springer.com/article/10.1007/s40801-016-0096-](https://link.springer.com/article/10.1007/s40801-016-0096-z)  
514 [z](https://link.springer.com/article/10.1007/s40801-016-0096-z)

515 20. Laporte JR, Healy D. Medications compromising Covid infections [Internet]. RxISK |  
516 Prescription Drug Side Effects. 2020 [cited 2022 Aug 23]. Available from:  
517 <https://rxisk.org/medications-compromising-covid-infections/>

518 21. May M, Slitzky M, Rostama B, Barlow D, Houseknecht KL. Antipsychotic-induced immune  
519 dysfunction: A consideration for COVID-19 risk. Brain, Behav Immun - Heal. 2020 Jul  
520 1;6:100097.

521 22. Reilev M, Kristensen KB, Pottegård A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and  
522 predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for  
523 SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol [Internet]. 2020 Oct 1 [cited  
524 2023 Jul 17];49(5):1468–81. Available from: <https://dx.doi.org/10.1093/ije/dyaa140>


525 23. Poblador-Plou B, Carmona-Pérez J, Ioakeim-Skoufa I, Poncel-Falcó A, Bliet-Bueno K, Cano-Del  
526 Pozo M, et al. Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19  
527 Cases: Results from the PRECOVID Study in Spain. Int J Environ Res Public Heal 2020, Vol 17,  
528 Page 5171 [Internet]. 2020 Jul 17 [cited 2023 Jul 17];17(14):5171. Available from:

- 529 <https://www.mdpi.com/1660-4601/17/14/5171/htm>
- 530 24. Cantudo-Cuenca MD, Gutiérrez-Pizarra A, Pinilla-Fernández A, Contreras-Macías E,  
531 Fernández-Fuertes M, Lao-Domínguez FA, et al. Drug–drug interactions between treatment  
532 specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first  
533 wave in Spain. *Sci Reports* 2021 111 [Internet]. 2021 Jun 14 [cited 2023 Jul 17];11(1):1–8.  
534 Available from: <https://www.nature.com/articles/s41598-021-91953-2>
- 535 25. Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI, Rubio-García A, Torelló-Iserte J,  
536 Crespo-Facorro B. Drug-drug interactions between COVID-19 treatments and antipsychotics  
537 drugs: integrated evidence from 4 databases and a systematic review. *Psychopharmacology*  
538 (Berl) [Internet]. 2021 Feb 1 [cited 2023 Jul 17];238(2):329–40. Available from:  
539 <https://pubmed.ncbi.nlm.nih.gov/33410987/>
- 540 26. Jeste S, Hyde C, Distefano C, Halladay A, Ray S, Porath M, et al. Changes in access to  
541 educational and healthcare services for individuals with intellectual and developmental  
542 disabilities during COVID-19 restrictions. *J Intellect Disabil Res* [Internet]. 2020 Nov 1 [cited  
543 2023 Jul 17];64(11):825–33. Available from:  
544 <https://onlinelibrary.wiley.com/doi/full/10.1111/jir.12776>
- 545 27. Sosenko F, Mackay D, Bhautesh DJ, Fleming M, Pell JP, Hatton C, et al. Understanding covid-  
546 19 outcomes among people with Intellectual Disabilities in England. *BMC Public Health*.  
547 2023;23(2099). Available from: <https://doi.org/10.1186/s12889-023-16993-x>
- 548 28. Henderson A, Fleming M, Cooper SA, Pell JP, Melville C, MacKay DF, et al. COVID-19 infection  
549 and outcomes in a population-based cohort of 17 203 adults with intellectual disabilities  
550 compared with the general population. *J Epidemiol Community Heal* [Internet]. 2022 Jun 1  
551 [cited 2023 Jul 17];76(6):550–5. Available from: <https://jech.bmj.com/content/76/6/550>
- 552 29. Gardner W, States D, Bagley N. The Coronavirus and the Risks to the Elderly in Long-Term  
553 Care. <https://doi.org/10.1080/0895942020201750543> [Internet]. 2020 Jul 3 [cited 2023 Jul  
554 17];32(4–5):310–5. Available from:  
555 <https://www.tandfonline.com/doi/abs/10.1080/08959420.2020.1750543>
- 556 30. Krieger I, Erez G, Weinstein O, Cohen AD, Tzur Bitan D. COVID-19 Morbidity Among  
557 Individuals with Autistic Spectrum Disorder: A Matched Controlled Population-Based Study. *J*  
558 *Autism Dev Disord* [Internet]. 2023 Feb 1 [cited 2023 Jul 17];53(2):789–94. Available from:  
559 <https://link.springer.com/article/10.1007/s10803-021-05187-2>
- 560 31. British Heart Foundation Data Science Centre [Internet]. Available from:  
561 <https://bhfdatasciencecentre.org/areas/cvd-covid-uk-covid-impact/>
- 562 32. Cassell A, Edwards D, Harshfield A, Rhodes K, Brimicombe J, Payne R, et al. The epidemiology  
563 of multimorbidity in primary care: a retrospective cohort study. *Br J Gen Pract* [Internet].  
564 2018 Apr 1 [cited 2023 Jul 17];68(669):e245–51. Available from:  
565 <https://bjgp.org/content/68/669/e245>
- 566 33. Public Health England. Deaths of people identified as having learning disabilities with COVID-  
567 19 in England in the spring of 2020 [Internet]. London; 2020. Available from:  
568 [https://www.gov.uk/government/publications/covid-19-deaths-of-people-with-learning-](https://www.gov.uk/government/publications/covid-19-deaths-of-people-with-learning-disabilities)  
569 [disabilities](https://www.gov.uk/government/publications/covid-19-deaths-of-people-with-learning-disabilities) (2020).
- 570 34. Kinnear D, Morrison J, Allan L, Henderson A, Smiley E, Cooper SA. Prevalence of physical  
571 conditions and multimorbidity in a cohort of adults with intellectual disabilities with and  
572 without Down syndrome: cross-sectional study. *BMJ Open* [Internet]. 2018 Feb 1 [cited 2023  
573 Jul 3];8(2):18292. Available from: [/pmc/articles/PMC5829598/](https://pmc/articles/PMC5829598/)

- 574 35. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic  
575 review of definitions. BMC Geriatr [Internet]. 2017 Oct 10 [cited 2023 Jul 17];17(1):1–10.  
576 Available from: <https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-017-0621-2>
- 577 36. Forsyth L, Mcorley M, Rydzewska E. All-cause and cause-specific mortality in people with  
578 autism spectrum disorder: A systematic review. Res Autism Spectr Disord [Internet]. 2023  
579 [cited 2023 Jul 3];105:102165. Available from: <http://creativecommons.org/licenses/by/4.0/>
- 580 37. Mehta H, Glover G. Psychotropic drugs and people with learning disabilities or autism  
581 [Internet]. Public Health England. 2019. Available from:  
582 [https://www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-](https://www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-disabilities-or-autism/psychotropic-drugs-and-people-with-learning-disabilities-or-autism-discussion#citation)  
583 [disabilities-or-autism/psychotropic-drugs-and-people-with-learning-disabilities-or-autism-](https://www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-disabilities-or-autism/psychotropic-drugs-and-people-with-learning-disabilities-or-autism-discussion#citation)  
584 [discussion#citation](https://www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-disabilities-or-autism/psychotropic-drugs-and-people-with-learning-disabilities-or-autism-discussion#citation)
- 585 38. Russell G, Stapley S, Newlove-Delgado T, Salmon A, White R, Warren F, et al. Time trends in  
586 autism diagnosis over 20 years: a UK population-based cohort study. J Child Psychol  
587 Psychiatry Allied Discip. 2022 Jun 1;63(6):674–82.
- 588 39. Github analysis plan [Internet]. Available from: [https://github.com/BHFDSC/CCU030\\_02](https://github.com/BHFDSC/CCU030_02)
- 589 40. Glover G, Williams R, Branford D, Avery R, Chauhan U, Hoghton M, et al. Prescribing of  
590 psychotropic drugs to people with learning disabilities and/or autism by general practitioners  
591 in England [Internet]. 2015. Available from:  
592 <http://webarchive.nationalarchives.gov.uk/20160704152031>
- 593 41. Carthy E, Ross C, Murphy D. Psychotropic medication prescribing in people with autism  
594 spectrum disorders with and without psychiatric comorbidity. [cited 2023 Oct 23]; Available  
595 from: <https://doi.org/10.1192/bja.2021.32>
- 596 42. Rahimi E, Hashemi Nazari SS. A detailed explanation and graphical representation of the  
597 Blinder-Oaxaca decomposition method with its application in health inequalities. Emerg  
598 Themes Epidemiol [Internet]. 2021 Dec 1 [cited 2023 Aug 15];18(1):1–15. Available from:  
599 <https://ete-online.biomedcentral.com/articles/10.1186/s12982-021-00100-9>
- 600 43. Lai MC, Lombardo M V., Baron-Cohen S. Autism. Lancet. 2014 Mar 8;383(9920):896–910.
- 601 44. Nicolaidis C, Raymaker D, McDonald K, Dern S, Boisclair WC, Ashkenazy E, et al. Comparison  
602 of healthcare experiences in autistic and non-autistic adults: A cross-sectional online survey  
603 facilitated by an academic-community partnership. J Gen Intern Med [Internet]. 2013 Jun 21  
604 [cited 2023 Jul 18];28(6):761–9. Available from:  
605 <https://link.springer.com/article/10.1007/s11606-012-2262-7>
- 606 45. Strydom A, Corcoran E, Rebillat AS. The COVID-19 pandemic should be last orders for poor  
607 care of people with neurodevelopmental disorders. Br J Psychiatry [Internet]. 2021 Jun 1  
608 [cited 2023 Jul 18];218(6):302–4. Available from:  
609 [https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/covid19-](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/covid19-pandemic-should-be-last-orders-for-poor-care-of-people-with-neurodevelopmental-disorders/A2776C8EDCCE04C4797EB1B528F1E8F7)  
610 [pandemic-should-be-last-orders-for-poor-care-of-people-with-neurodevelopmental-](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/covid19-pandemic-should-be-last-orders-for-poor-care-of-people-with-neurodevelopmental-disorders/A2776C8EDCCE04C4797EB1B528F1E8F7)  
611 [disorders/A2776C8EDCCE04C4797EB1B528F1E8F7](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/covid19-pandemic-should-be-last-orders-for-poor-care-of-people-with-neurodevelopmental-disorders/A2776C8EDCCE04C4797EB1B528F1E8F7)
- 612 46. Saqr Y, Braun E, Porter K, Barnette D, Hanks C. Addressing medical needs of adolescents and  
613 adults with autism spectrum disorders in a primary care setting. Autism [Internet]. 2018 Jan 1  
614 [cited 2023 Jul 18];22(1):51–61. Available from:  
615 <https://journals.sagepub.com/doi/10.1177/1362361317709970>
- 616 47. Nakhaee HI, Zangiabadian MI, Bayati R, Rahmanian M, Ghaffari Jolfayi A, Rakhshanderou S.  
617 The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A

- 618 systematic review and meta-analysis. 2022 [cited 2023 Jul 18]; Available from:  
619 <https://doi.org/10.1371/journal.pone.0267423>
- 620 48. Hoertel N, Sánchez-Rico M, Vernet R, Nathanaël Beeker •, Jannot A-S, Neuraz A, et al.  
621 Association between antidepressant use and reduced risk of intubation or death in  
622 hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry  
623 [Internet]. 2021 [cited 2023 Jul 18];26:5199–212. Available from:  
624 <https://doi.org/10.1038/s41380-021-01021-4>
- 625 49. NHS England Secure Data Environment Service [Internet]. Available from:  
626 <https://digital.nhs.uk/services/secure-data-environment-service>
- 627 50. BHF Data Science Centre [Internet]. Available from: <https://bhfdatasciencecentre.org/>
- 628 51. NHS England IGARD [Internet]. Available from: [https://digital.nhs.uk/about-nhs-](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data)  
629 [digital/corporate-information-and-documents/independent-group-advising-on-the-release-](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data)  
630 [of-data](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data)
- 631 52. NHS Digital DARS [Internet]. Available from: [https://digital.nhs.uk/services/data-access-](https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-services)  
632 [request-service-dars/dars-products-and-services](https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-services).
- 633 53. Kenny L, Hattersley C, Molins B, Buckley C, Povey C, Pellicano E. Which terms should be used  
634 to describe autism? Perspectives from the UK autism community.  
635 <http://dx.doi.org/10.1177/1362361315588200> [Internet]. 2015 Jul 1 [cited 2023 Jul  
636 18];20(4):442–62. Available from:  
637 [https://journals.sagepub.com/doi/10.1177/1362361315588200?url\\_ver=Z39.88-](https://journals.sagepub.com/doi/10.1177/1362361315588200?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed)  
638 [2003&rfr\\_id=ori%3Arid%3Acrossref.org&rfr\\_dat=cr\\_pub++0pubmed](https://journals.sagepub.com/doi/10.1177/1362361315588200?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed)
- 639

Figure 1. Visualisation of Blinder-Oaxaca Decomposition analysis.



## Tables

*Table 1. Demographic and health characteristics of autistic and general population people hospitalised with a registered positive COVID-19 test.*

	General population (n = 8,425,470)	Autistic population (n = 32,375)			
		Adjusted	P-value	Unadjusted	P-value
Age [Mdn., IQR]	41.8 [30.0, 55.0]	-	-	24.9 [21.0, 31.5]	<0.001
Female (%)	54.0	33.7	<0.001	33.4	<0.001
Mean IMD decile (SD)	5.4 (2.9)	5.0 (2.8)	<0.001	5.1 (2.9)	<0.001
<i>Ethnicity (%)</i>			<0.001		<0.001
White	82.7	93.5		92.0	
Asian	9.2	2.2		2.4	
Black	3.7	1.6		2.0	
Mixed	1.9	1.6		2.4	
Other	2.4	1.1		1.3	
<i>Vaccine</i>			0.8		<0.001
AstraZeneca	21.2	23.4		30.1	
Moderna	3.4	3.1		7.6	
Pfizer	26.4	24.4		62.2	
<i>Vaccine doses</i>			>0.9		<0.001
0	49.3	49.1		50.8	
1	18.3	18.4		19.4	
2	32.5	32.5		29.8	
<i>Total number of prescribed medications</i>			<0.001		<0.001
0	55.8	36.1		53.4	
1-3	23.0	24.4		25.8	
4-6	9.3	14.5		10.4	
7-9	4.9	9.0		4.9	
10+	7.0	16.1		5.4	
Mean prescription medications (SD)	2.9 (4.5)	5.1 (6.0)	<0.001	2.7 (3.6)	0.002
Polypharmacy (%)	21.2	39.5	<0.001	20.8	0.14
<i>Medications split by class</i>			<0.001		-
On Psychotropics (%)					
No	80.9	49.7		-	
Yes	19.1	50.3		-	
Antipsychotics (%)	1.3	12.7	<0.001	-	-

Antidepressants (%)	17.1	45.1	<0.001	-	-
Anticonvulsants (%)	3.9	11.7	<0.001	-	-
<b>Morbidity</b>					
Mean LTCs (SD)	1.0 (3.0)	2.4 (4.0)	<0.001	1.2 (2.7)	<0.001
Multimorbidity (%)	11.9	24.3	<0.001	12.4	<0.001

Table 2. Standardised Incidence Ratios for autistic adults with general population as reference.

	COVID-19 Hospitalisation				Severe COVID-19			
	Observed	Expected	Excess	SIR [95% CI]	Observed	Expected	Excess	SIR [95% CI]
Mar-Dec 2020	372	234	138	1.6 [1.4, 1.7]	382	244	138	1.6 [1.4, 1.7]
Jan-Dec 2021	603	461	142	1.3 [1.2, 1.4]	620	469	151	1.3 [1.2, 1.4]

Table 3. Age Standardised Mortality Rates (ASMR) for the adult autistic and general population in study sample as compared to the European Standard Population 2013. Second column shows Standardised Mortality Ratios (SMR) for the autistic population as compared to the general population for the study sample only. Observed, expected and excess mortality for SMRs are shown.

	ASMR [95% CI]		SMR [95% CI]			
	Autistic population	General population	Autistic population	Observed	Expected	Excess
Mar-Dec 2020	278.9 [278, 278]	166.2 [166, 166]	1.52 [1.04, 2.0]	39	25.6	13.4
Jan-Dec 2021	271.5 [271, 271]	143.1 [143, 143]	1.34 [0.93, 1.74]	42	31.5	10.5

*Table 4.* Results from the logistic models A and B fit to the autistic and general population separately.

[illegible]

Count of long-term conditions	1.550 [1.548, 1.551]	<.001	1.570 [1.543, 1.597]	<.001	1.370 [1.369, 1.370]	<.001	1.436 [1.419, 1.453]	<.001
Count of prescription medicines	1.101 [1.100, 1.102]	<.001	1.084 [1.057, 1.111]	<.001	-	-	-	-
Interaction of the above two counts	0.984 [0.984, 0.984]	<.001	0.985 [0.982, 0.988]	<.001	-	-	-	-
Prescription medication by class								
Antipsychotic	-	-	-	-	1.713 [1.693, 1.733]	<.001	1.262 [1.044, 1.479]	.03
Antidepressant	-	-	-	-	0.867 [0.857, 0.876]	<.001	0.643 [0.475, 0.811]	<.001
Anticonvulsant	-	-	-	-	1.082 [1.068, 1.095]	<.001	1.028 [0.805, 1.250]	.81
Constant	0.005 [-0.010, 0.020]	<.001	0.004 [-0.252, 0.260]	<.001	0.006 [-0.009, 0.020]	<.001	0.006 [-0.201, 0.214]	<.001
Observations	8,259,596	-	31,758	-	8,259,596		31,782	

Table 5. Results from the Cox proportional hazards model for model A and B.

<b>Model A</b>								
<b>Variables</b>	<b>General population</b>				<b>Autistic population</b>			
	<b>β</b>	<b>SE</b>	<b>Exp(β) [95% CI lower, upper]</b>	<b>P-value</b>	<b>β</b>	<b>SE</b>	<b>Exp(β) [95% CI lower, upper]</b>	<b>P-value</b>
Age at COVID-19	.03	.0001	1.03 [1.03, 1.03]	<.001	.03	.003	1.03 [1.02, 1.03]	<.001
Female	-.37	.003	.69 [.69, .69]	<.001	-.28	.087	.75 [.63, .89]	.001
IMD decile	-.03	.0006	.97 [.97, .98]	<.001	-			
<b>Ethnicity</b>								
White					(base)			
Asian	.51	.005	1.67 [1.65, 1.69]	<.001	.76	.215	2.13 [1.40, 3.24]	<.001
Black	.59	.008	1.81 [1.78, 1.84]	<.001	.21	.240	1.24 [.77, 1.98]	.37
Mixed	.39	.014	1.47 [1.43, 1.51]	<.001	-.14	.282	.87 [.50, 1.51]	.61
Other	.59	.011	1.81 [1.77, 1.85]	<.001	.01	.337	1.01 [.52, 1.95]	.98
<b>Vaccinations</b>								
Number of doses	-.23	.008	.80 [.78, .81]	<.001	-.48	.205	.62 [.41, .92]	.01
AstraZeneca	-.48	.015	.62 [.60, .64]	<.001	-.09	.394	.92 [.42, 1.99]	.83
Pfizer	-.95	.012	.39 [.38, .40]	<.001	-1.03	.314	.36 [.19, .66]	.001
Moderna	-1.93	.034	.15 [.14, .16]	<.001	-2.04	.748	.13 [.03, .56]	.006
<b>Interactions</b>								
Count of long-term conditions	0.22	.0006	1.25 [1.25, 1.25]	<.001	.35	.012	1.42 [1.38, 1.45]	<.001
Count of prescription medicines	.03	.0006	1.03 [1.03, 1.03]	<.001	.09	.015	1.09 [1.06, 1.12]	<.001
Interaction of the above two counts	-.006	.00006	.99 [.99, .99]	<.001	-.01	.002	.99 [.99, .99]	<.001

Model B								
Variables	General population				Autistic population			
	β	SE	HR [95% CI lower, upper]	P-value	β	SE	HR [95% CI lower, upper]	P-value
Age at COVID-19	.025	.0001	1.03 [1.03, 1.03]	<.001	.03	.002	1.03 [1.02, 1.03]	<.001
Female	-.35	.003	.70 [.70, .71]	<.001	-.19	.086	.83 [.70, .98]	.03
IMD decile	-.03	.001	.97 [.97, .97]	<.001	-			
Ethnicity								
White	(base)							
Asian	.49	.005	1.64 [1.62, 1.65]	<.001	.77	.215	2.14 [1.41, 3.28]	<.001
Black	.57	.008	1.77 [1.74, 1.79]	<.001	.17	.241	1.19 [.74, 1.90]	.48
Mixed	.37	.014	1.45 [1.41, 1.49]	<.001	-.05	.282	.95 [.54, 1.65]	.85
Other	.58	.011	1,78 [1.75, 1.82]	<.001	.11	.337	1.12 [.58, 2.16]	.75
Vaccinations								
Number of doses	-.22	.008	.80 [.79, .81]	<.001	-.45	.203	.64 [.43, .95]	.03
AstraZeneca	-.48	.015	.62 [.60, .64]	<.001	-.15	.390	.86 [.40, 1.85]	.70
Pfizer	-.95	.012	.39 [.38, .40]	<.001	-1.12	.314	.33 [.18, .60]	<.001
Moderna	-1.95	.034	.14 [.13, .15]	<.001	-2.13	.750	.12 [.03, .52]	.004
LTCs								
Count of long-term conditions	.17	.0004	1.19 [1.19, 1.19]	<.001	.28	.008	1.32 [1.30, 1.34]	<.001
Prescribed medications by class								
Antipsychotic medication	-.01	.007	.99 [.97, 1.0]	.07	.02	.115	1.02 [.82, 1.28]	.85
Antidepressive medication	-.17	.004	.85 [.84, .85]	<.001	-.24	.086	.78 [.66, .93]	.005
Anticonvulsive medication	.04	.005	1.04 [1.03, 1.05]	<.001	.11	.111	1.12 [.90, 1.39]	.30

*Table 6.* Results from the hierarchical logistic regression showing Pseudo R<sup>2</sup>, Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). Vaccine status is defined by the presence or absence of at least one COVID-19 vaccination.

	Autistic population			General population		
	Pseudo R2	AIC	BIC	Pseudo R2	AIC	BIC
Age	0.091	8353	8370	0.232	30871388	30871666
+ sex	0.093	8340	8365	0.234	30789963	30790381
+ ethnicity	0.094	8336	8394	0.241	30524687	30525662
+ IMD decile	0.095	8326	8393	0.248	30241212	30242327
+ vaccine status	0.145	7880	7989	0.297	28292202	28294012
+ LTC count	0.224	7160	7277	0.364	25565855	25567805
+ polypharmacy	0.225	7146	7272	0.369	25358599	25360689

